Across TCGA pan-cancer cohorts, CLN6 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CLN6 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLN6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLN6 expression acts as an unfavorable survival marker.
LUAD are the cancer types where CLN6 Mutation most reproducibly stratifies survival.